Innovative combination Finasteride + Tadalafil

Innovative combination Finasteride + Tadalafil  

• Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe. 
• The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of therapeutic effect and reduction of finasteride-induced adverse events (e.g. erectile dysfunction) 
• Co-administration of Tadalafil 5 mg and finasteride 5 mg is recommended by European association of Urology (EAU – Guideline for Management of Non-neurogenic Male LUTS)  and approved by FDA for BPH for up to 26 weeks 
• For more details contact Vaibhav Sharma, Head of Value added products ([email protected] )